GO:2000480 negative regulation of cAMP-dependent protein kinase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000480 describes any process that stops, prevents, or reduces the frequency, rate, or extent of cAMP-dependent protein kinase (PKA) activity.
• Negative regulation of PKA is essential for controlling cardiac contractility, skeletal muscle plasticity, immune signaling, and neuronal function.
• Key mechanisms include degradation of PKA catalytic subunits by calpain, sequestration by regulatory subunits, and inhibition via phosphodiesterases that lower cAMP.
• Dysregulation of PKA negative regulation is linked to heart failure, Alzheimer disease, and inflammatory disorders.
• CRISPR knockout, point mutation, and knock-in models enable precise dissection of PKA regulatory networks.
• EDITGENE provides custom cell models and library screening to study negative regulation of PKA in disease contexts.
Description
The Gene Ontology term GO:2000480, negative regulation of cAMP-dependent protein kinase activity, defines any process that stops, prevents, or reduces the frequency, rate, or extent of cAMP-dependent protein kinase (PKA) activity. PKA is a serine/threonine kinase activated by cyclic AMP (cAMP) that phosphorylates numerous substrates to control metabolism, gene expression, cell growth, and differentiation. Because unrestrained PKA signaling can drive pathological cardiac hypertrophy, muscle wasting, and neuroinflammation, negative regulation of PKA is critical for cellular homeostasis. This article synthesizes published evidence on the mechanisms, genes, and experimental models used to study this process.
negative regulation of cAMP-dependent protein kinase activity At A Glance
| GO ID | GO:2000480 |
|---|---|
| GO term | negative regulation of cAMP-dependent protein kinase activity |
| Ontology | biological_process |
| Synonym | negative regulation of PKA; negative regulation of protein kinase A activity; negative regulation of STK22 |
| Major function | Reduces PKA catalytic activity to modulate downstream signaling |
| Related kinases | PKA (PRKACA, PRKACB, PRKACG), PKI (PKIA, PKIB, PKIG) |
| Key regulators | Calpain, phosphodiesterases (PDEs), regulatory subunits (PRKAR1A, PRKAR2A/B) |
| Disease relevance | Heart failure, Alzheimer disease, inflammation, muscle atrophy |
What Is GO:2000480?
GO:2000480 is a biological process term that encompasses any molecular event that reduces the activity of cAMP-dependent protein kinase (PKA). This includes degradation of PKA catalytic subunits, inhibition by regulatory subunits, dephosphorylation, and reduction of intracellular cAMP levels that normally activate PKA. The term is not restricted to a single mechanism but covers all physiological and pathological processes that negatively regulate PKA catalytic activity.
Why Is negative regulation of cAMP-dependent protein kinase activity Important in Cell Biology?
Negative regulation of PKA is essential for preventing excessive phosphorylation of downstream targets that can lead to cardiac arrhythmias, heart failure, and metabolic disorders. In the immune system, it controls T-cell receptor activation and inflammatory cytokine production. In the brain, loss of PKA negative regulation contributes to tau hyperphosphorylation and neurodegeneration. Understanding this process provides therapeutic targets for a wide range of diseases.
• Prevents pathological cardiac hypertrophy and heart failure by limiting PKA-driven contractility.
• Regulates skeletal muscle plasticity and prevents muscle wasting through FoxO inhibition.
• Controls T-cell activation and inflammatory responses via the cAMP-PKA-Csk pathway.
• Protects against Alzheimer disease by reducing calpain-mediated PKA degradation.
• Modulates pain signaling through Cav3.2 T-type calcium channels.
• Influences developmental processes in model organisms such as Polysphondylium pallidum.
• Provides a mechanism for cross-talk between cAMP and other signaling pathways.
• Dysregulation is implicated in cancer, neurodegeneration, and immune disorders.
What Happens During negative regulation of cAMP-dependent protein kinase activity?
Reduction of intracellular cAMP levels
In simple terms: Lowering cAMP turns off PKA.
PKA is activated by cAMP binding to its regulatory subunits. Negative regulation often begins with phosphodiesterases (PDEs) that hydrolyze cAMP, reducing its availability and thereby decreasing PKA activity. In cardiac hypertrophy, PDE10A-mediated cAMP degradation attenuates PKA signaling downstream of A2AR-D2R dimers.
Degradation of PKA catalytic subunits
In simple terms: Destroying the enzyme stops its activity.
In Alzheimer disease brain, over-activated calpain cleaves the catalytic subunit of PKA, leading to down-regulation of PKA activity. This proteolytic mechanism represents a direct negative regulation of PKA protein levels.
Inhibition by regulatory subunits and PKI
In simple terms: Binding partners block PKA.
The RIα subunit of PKA (PRKAR1A) sequesters catalytic subunits and modulates cardiac contractility; its loss leads to increased PKA activity and heart failure. Additionally, protein kinase inhibitor (PKI) peptides bind to the catalytic subunit and inhibit its activity, though specific PMIDs for PKI in this context are not included in the verified list.
Dephosphorylation of PKA substrates
In simple terms: Removing phosphate groups reverses PKA effects.
While not directly inhibiting PKA catalytic activity, phosphatases can counteract PKA-mediated phosphorylation. This is a downstream negative feedback mechanism that reduces the functional output of PKA signaling.
Key Genes Involved in GO:2000480 negative regulation of cAMP-dependent protein kinase activity
The following genes and proteins are central to the negative regulation of cAMP-dependent protein kinase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKAR1A | Regulatory subunit that binds and inhibits PKA catalytic subunits | Cardiac contractility and heart failure |
| PRKACA | Catalytic subunit of PKA; target of negative regulation | Skeletal muscle plasticity and FoxO regulation |
| PRKACB | Catalytic subunit of PKA; target of negative regulation | T-cell receptor signaling |
| PRKACG | Catalytic subunit of PKA; target of negative regulation | Not directly cited in verified list |
| PKIA | Protein kinase inhibitor, binds and inhibits PKA catalytic subunit | Not directly cited in verified list |
| PKIB | Protein kinase inhibitor, binds and inhibits PKA catalytic subunit | Not directly cited in verified list |
| PKIG | Protein kinase inhibitor, binds and inhibits PKA catalytic subunit | Not directly cited in verified list |
| PDE10A | Phosphodiesterase that degrades cAMP, reducing PKA activity | Cardiac hypertrophy |
| CAPN1 | Calpain protease that degrades PKA catalytic subunit | Alzheimer disease |
| FOXO | Transcription factor inhibited by PKA; negative regulation of PKA affects FoxO | Skeletal muscle plasticity |
| CSK | C-terminal Src kinase, part of cAMP-PKA-Csk negative feedback in T cells | T-cell activation |
| CACNA1H | Cav3.2 T-type calcium channel, modulated by PKA | Pain signaling |
| RANTES | Chemokine whose transcription is negatively regulated by PKA via Raf | Inflammation |
| PRKAR2A | Regulatory subunit of PKA | Not directly cited in verified list |
| PRKAR2B | Regulatory subunit of PKA | Not directly cited in verified list |
| AKAPs | A-kinase anchoring proteins that localize PKA and regulatory factors | Not directly cited in verified list |
| ADCY | Adenylyl cyclase, produces cAMP; upstream of PKA | Not directly cited in verified list |
How Is negative regulation of cAMP-dependent protein kinase activity Regulated?
Negative regulation of PKA activity is itself regulated at multiple levels. Phosphodiesterases such as PDE10A hydrolyze cAMP, reducing PKA activation. Calpain-mediated proteolysis of the PKA catalytic subunit provides an irreversible off-switch in neurodegenerative conditions. Regulatory subunits like PRKAR1A set the threshold for PKA activation and are essential for cardiac homeostasis. Additionally, feedback loops involving Csk in T cells modulate PKA signaling.
negative regulation of cAMP-dependent protein kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKAR1A | Heart failure | Cardiac-specific knockout mouse |
| PDE10A | Cardiac hypertrophy | Overexpression in cardiomyocytes |
| CAPN1 | Alzheimer disease | Calpain overactivation in neuronal cells |
| PRKACA | Skeletal muscle plasticity | Muscle-specific knockout |
| CSK | T-cell activation | Jurkat T cell knockout |
Heart failure and cardiac hypertrophy
Loss of PRKAR1A, the RIα regulatory subunit of PKA, leads to increased PKA activity and development of heart failure in mice. Similarly, PDE10A-mediated cAMP degradation, which reduces PKA activity, is protective against cardiac hypertrophy. These findings highlight negative regulation of PKA as a therapeutic target in cardiovascular disease.
Alzheimer disease
In Alzheimer disease brain, over-activated calpain degrades the catalytic subunit of PKA, leading to down-regulation of PKA activity. This loss of PKA function may contribute to synaptic dysfunction and neurodegeneration.
Inflammation and immune disorders
PKA negatively regulates RANTES-mediated transcription of proinflammatory mediators through Raf, and inhibition of PKA enhances inflammatory responses. In T cells, the cAMP-PKA-Csk pathway negatively regulates T-cell receptor activation, and disruption of this pathway leads to aberrant immune activation.
From negative regulation of cAMP-dependent protein kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PRKAR1A increase PKA activity and cause heart failure? | PRKAR1A knockout mouse |
| Does PDE10A overexpression reduce PKA activity and prevent hypertrophy? | PDE10A overexpression in cardiomyocytes |
| Does calpain-mediated PKA degradation contribute to Alzheimer disease? | Calpain overactivation in neuronal cultures |
| Does PKA inhibition affect FoxO and muscle plasticity? | PKA catalytic subunit knockout in skeletal muscle |
| Does PKA negatively regulate RANTES transcription? | PKA inhibitor treatment in inflammatory cells |
| Does PKA modulate Cav3.2 channels? | PKA activator/inhibitor in sensory neurons |
How to Study the negative regulation of cAMP-dependent protein kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PKA kinase assay | Catalytic activity of PKA | Quantify negative regulation in cell lysates |
| cAMP ELISA | Intracellular cAMP concentration | Assess phosphodiesterase activity |
| Western blot | Protein expression and phosphorylation | Detect PKA subunit degradation |
| Co-immunoprecipitation | Protein-protein interactions | Study regulatory subunit binding |
| CRISPR knockout screen | Gene function on a global scale | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Measure downstream effects of PKA inhibition |
| FRET biosensor | Real-time PKA activity | Live-cell imaging of PKA dynamics |
| Calpain activity assay | Protease activity | Measure PKA degradation in neurodegeneration |
Kinase activity assays
PKA activity can be measured using radioactive or fluorescent kinase assays with specific substrates. These assays quantify the balance between PKA and its negative regulators.
cAMP measurement
Intracellular cAMP levels are measured by ELISA or FRET-based biosensors to assess upstream regulation of PKA.
Western blotting and immunoprecipitation
Protein levels of PKA subunits and regulatory proteins are assessed by Western blotting; interactions are studied by co-immunoprecipitation.
CRISPR-based genetic screens
Genome-wide CRISPR knockout libraries can identify genes whose loss alters PKA activity, revealing novel negative regulators.
How CRISPR Can Be Used to Study GO:2000480 negative regulation of cAMP-dependent protein kinase activity
Knockout
CRISPR knockout of PRKAR1A or PDE10A can be used to study loss of negative regulation of PKA and its consequences in cardiac or neuronal cells.
Point Mutation
Point mutations in the catalytic subunit of PKA (PRKACA) can mimic constitutive activation or inhibition, allowing precise dissection of negative regulatory mechanisms.
Knock-in
Knock-in of tagged PKA subunits (e.g., GFP-PRKACA) enables live-cell imaging and interaction studies to monitor negative regulation in real time.
Overexpression
Overexpression of PKI or phosphodiesterases can suppress PKA activity, providing a gain-of-function approach to study negative regulation.
How EDITGENE Supports negative regulation of cAMP-dependent protein kinase activity Research
Researchers studying negative regulation of cAMP-dependent protein kinase activity-related genes often need to determine whether a candidate gene is causally involved in PKA suppression, and to dissect the precise molecular mechanisms in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cAMP-dependent protein kinase activity research.
Frequently Asked Questions About negative regulation of cAMP-dependent protein kinase activity
What is GO:2000480?
GO:2000480 is a Gene Ontology biological process term for any process that stops, prevents, or reduces the frequency, rate, or extent of cAMP-dependent protein kinase (PKA) activity.
What genes are involved in negative regulation of cAMP-dependent protein kinase activity?
Key genes include PRKAR1A, PDE10A, CAPN1, PKIA, PKIB, PKIG, and CSK, among others.
How is PKA activity negatively regulated?
PKA activity can be reduced by cAMP degradation via phosphodiesterases, proteolytic degradation of catalytic subunits by calpain, and binding of inhibitory proteins like PKI.
Why is negative regulation of PKA important in the heart?
Loss of PKA negative regulation leads to increased PKA activity, cardiac contractility defects, and heart failure.
What diseases are associated with dysregulated PKA negative regulation?
Heart failure, Alzheimer disease, inflammatory disorders, and muscle atrophy have been linked to altered PKA negative regulation.
How can CRISPR be used to study negative regulation of PKA?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes like PRKAR1A and PDE10A to study their effects on PKA activity.
What is the role of calpain in PKA regulation?
Calpain overactivation degrades the PKA catalytic subunit, leading to down-regulation of PKA activity in Alzheimer disease brain.
Does PKA negatively regulate inflammation?
Yes, PKA negatively regulates RANTES-mediated transcription of proinflammatory mediators through Raf.
What is the role of PDE10A in PKA regulation?
PDE10A hydrolyzes cAMP, reducing PKA activity and protecting against cardiac hypertrophy.
How does PKA affect T-cell activation?
The cAMP-PKA-Csk pathway negatively regulates T-cell receptor activation in lipid rafts.
Conclusion
Negative regulation of cAMP-dependent protein kinase activity (GO:2000480) is a critical biological process that prevents excessive PKA signaling. Dysregulation of this process contributes to heart failure, neurodegeneration, and inflammatory diseases. CRISPR-based models and high-throughput screening are powerful tools to dissect the underlying mechanisms and identify therapeutic targets. EDITGENE offers comprehensive services to support this research.
References
- 1. Bedioune I et al.. 2024. Essential Role of the RIα Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development.. Circulation 150(25):2031-2045 PMID: 39355927
- 2. Chen S et al.. 2025. Role of A(2A)R-D2R Dimerization and D(2)R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.. Circulation 152(19):1371-1392 PMID: 40970278
- 3. Silveira WA et al.. 2020. cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice.. FASEB J 34(9):12946-12962 PMID: 32772437
- 4. Zhang Y et al.. 2003. Negative role of cAMP-dependent protein kinase A in RANTES-mediated transcription of proinflammatory mediators through Raf.. FASEB J 17(6):734-6 PMID: 12586731
- 5. Kim JA et al.. 2006. Augmentation of Cav3.2 T-type calcium channel activity by cAMP-dependent protein kinase A.. J Pharmacol Exp Ther 318(1):230-7 PMID: 16569752
- 6. Liang Z et al.. 2007. Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain.. J Neurochem 103(6):2462-70 PMID: 17908236
- 7. Tasken K et al.. 2006. Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts.. Front Biosci 11:2929-39 PMID: 16720365
- 8. Funamoto S et al.. 2003. cAMP-dependent protein kinase regulates Polysphondylium pallidum development.. Differentiation 71(1):51-61 PMID: 12558603
